Lacy Brian E, Levy L Campbell
Section of Gastroenterology & Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Clin Interv Aging. 2008;3(2):357-64. doi: 10.2147/cia.s2938.
Chronic constipation is highly prevalent, reduces patients' quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue ofprostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.
慢性便秘非常普遍，会降低患者的生活质量，并给社会带来巨大的医疗负担。生活方式的改变和非处方药物可改善部分患者的便秘症状，然而许多患者症状持续存在，需要使用处方药。目前有三种处方药已获美国食品药品监督管理局（FDA）批准，可用于治疗成人慢性便秘。本综述将聚焦于鲁比前列酮，这是治疗慢性便秘的最新药物。鲁比前列酮是前列腺素E1的双环脂肪酸代谢物类似物。它激活胃肠道中的特定氯离子通道，以刺激肠道液体分泌，增加胃肠道蠕动，并改善便秘症状。本文将简要概述胃肠道中氯离子通道的功能，描述鲁比前列酮的结构、功能和药代动力学，并讨论这种新药的安全性和有效性。
